The FDA approved Merck & Co.’s Welireg plus Keytruda combination as an adjuvant treatment for intermediate-high or high-risk clear cell renal cell carcinoma following kidney removal surgery. The approval marks the first regulatory nod for a PD-1 plus HIF-2α inhibitor combination in the adjuvant setting, positioning the regimen earlier in the disease course. Merck pointed to the pivotal Litespark-022 trial, which randomized 1,841 patients to Welireg plus Keytruda versus Keytruda plus placebo. The company reported a 28% reduction in risk of disease recurrence, metastasis, or death, with disease-free survival estimates of 81% versus 74% in the control arm. Overall survival data were described as not yet mature. Clinicians and advocates emphasized the potential to reduce the probability of recurrence-driven treatment switching in at-risk patients, while Merck positions the combo as a foundation for earlier-stage ccRCC management.